University College Hospital

Global Leaders in Cancer Research and Biotech Join The Mark Foundation for Cancer Research's Scientific Advisory and Industry Advisory Committees

Retrieved on: 
Tuesday, April 2, 2024
Molecule, Medicine, Cancer Research UK, FRS, Weill Cornell Medicine, Francis Crick Institute, B cell, Patient, Investment, Children's National Hospital, Therapy, Research, Biotechnology, Genentech, Dana–Farber Cancer Institute, Committee, Trial of the century, University, University College Hospital, Metastasis, Multiple sclerosis, Drug discovery, MBBS, Chairperson, MD, University College London, Senior, FRCP, University of California, Berkeley, Hospital, Nationwide Children's Hospital, Marker beacon, Diagnosis, Lung cancer, Ludwig Cancer Research, University of Pennsylvania, Doctor of Philosophy, BTK, GV (company), Celera Corporation, Pharmaceutical industry

NEW YORK, April 2, 2024 /PRNewswire/ -- The Mark Foundation for Cancer Research, a leading nonprofit dedicated to advancing research that transforms the prevention, diagnosis, and treatment of cancer, proudly announces the appointment of new members to its Scientific Advisory and Industry Advisory Committees.

Key Points: 
  • The committee assists the foundation in reviewing its scientific goals and grant applications, as well as providing strategic advice and support for its research programs and investments.
  • "The outstanding researchers on our advisory committees provide invaluable guidance and insight to help steer its programs toward success and impact."
  • "The Mark Foundation's funding of high-risk, high-impact research is essential in the quest to achieve real breakthroughs in cancer research," said Johanna Joyce, PhD.
  • "I am honored to join the Scientific Advisory Committee, to support the next generations of scientists and projects that will revolutionize treatments for patients."

HLTH EUROPE AND GE HEALTHCARE UNVEIL GROUNDBREAKING ART GALLERY: A FUSION OF HEALTHCARE AND CREATIVITY

Retrieved on: 
Monday, February 19, 2024
Caregiver, RAI, UCLH, Art, Photography, University College Hospital, Health care, Creativity, Painting, Patient, GE HealthCare

LONDON, Feb. 19, 2024 /PRNewswire/ -- HLTH Inc., the leading healthcare ecosystem platform, today announced the launch of the HLTH Europe Art Gallery, sponsored by GE HealthCare, a global leader in innovative healthcare solutions. Healthcare professionals, patients and caregivers are invited to submit their artwork here to be displayed at the HLTH Europe Art Gallery, held at the inaugural HLTH Europe event.

Key Points: 
  • Submissions for Europe's first digital and in person, cross-border art gallery are now open
    LONDON, Feb. 19, 2024 /PRNewswire/ -- HLTH Inc ., the leading healthcare ecosystem platform, today announced the launch of the HLTH Europe Art Gallery, sponsored by GE HealthCare , a global leader in innovative healthcare solutions.
  • Healthcare professionals, patients and caregivers are invited to submit their artwork here to be displayed at the HLTH Europe Art Gallery, held at the inaugural HLTH Europe event.
  • "We are thrilled to launch the HLTH Europe Art Gallery with the support of the GE HealthCare team," says Katy Fryatt, Managing Director, HLTH Europe.
  • The HLTH Europe Art Gallery will be open to all attendees across the three-day event at the RAI, Amsterdam from 17-20 June 2024.

Targeted Oncology™ announces recipients of its Oncology Icons award program

Retrieved on: 
Wednesday, November 15, 2023
Research, FACP, State university system, Royal college, University College Hospital, FCS, Hematology, Therapy, Urology, Internal medicine, Patient, Multimedia, Science, Gynaecology, Brooklyn Hospital Center, State, University of Ibadan, University, Survival, University College Hospital, Ibadan, Cornwall Regional Hospital, Brown, Quality of life, Committee on Finance, Nursing

CRANBURY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, is thrilled to announce the distinguished recipients of the prestigious Oncology Icons award program.

Key Points: 
  • CRANBURY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, is thrilled to announce the distinguished recipients of the prestigious Oncology Icons award program.
  • This program recognizes individuals who have made exceptional contributions to the field of oncology through their expertise, dedication and innovation.
  • “We are honored to acknowledge the outstanding contributions of these Oncology Icons,” said Erik Lohrmann, senior vice president of, oncology and urology.
  • Submissions for the Oncology Icons award program are accepted on a rolling basis throughout the year.

GE HealthCare Introduces Vscan Air SL, a Wireless Handheld Ultrasound Device for Rapid Assessments of Cardiac and Vascular Patients

Retrieved on: 
Friday, August 25, 2023
Research, Medical Devices, Health Technology, Cardiology, Biometrics, Biotechnology, Pharmaceutical, Health, Science, Other Science, GE HealthCare, FRCP, Workflow, Cardiovascular disease, GE, European Society of Cardiology, SL, Radiology, University College Hospital, General practice, Patient, Diagnosis, ESC, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Disease, Medical imaging

GE HealthCare (Nasdaq: GEHC) today announced the launch of Vscan Air SL – a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care to help clinicians accelerate diagnoses and treatment decisions.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) today announced the launch of Vscan Air SL – a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care to help clinicians accelerate diagnoses and treatment decisions.
  • View the full release here: https://www.businesswire.com/news/home/20230824324963/en/
    The Vscan Air SL is a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care.
  • In 2021, GE HealthCare introduced one of the smallest and most lightweight handheld ultrasound devices with the Vscan Air CL.
  • For more information about the GE HealthCare Vscan Air wireless handheld ultrasound, please visit gehealthcare.com .

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Retrieved on: 
Sunday, June 25, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, PK, Abstract, Priority review, Hematology, Head, European Medicines Agency, TAK, Confidence, Pharmacokinetics, Cmax, University College Hospital, Abdominal pain, Female, EMA, Congress, Incidence, Thrombocytopenia, Patient, TTP, Mortality, Ageing, Thrombosis, FDA, Headache, Safety, BLA, International Society on Thrombosis and Haemostasis, SD, International Society, TSE, Disease, Pharmaceutical industry, Takeda, Toll, ISTH, ADAMTS13

In the pivotal trial, no patient had an acute TTP event while receiving TAK-755 prophylactic treatment.

Key Points: 
  • In the pivotal trial, no patient had an acute TTP event while receiving TAK-755 prophylactic treatment.
  • In the pivotal trial, treatment-emergent adverse events (TEAEs) were reported in 10.3% of patients ages 12-68 receiving TAK-755 compared to 50% of patients receiving plasma-based therapy.
  • (Presentation Number: OC 14.4)
    Results were presented today in three oral presentations delivered at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress.
  • The FDA has accepted and granted Priority Review for Takeda’s Biologics License Application (BLA) for TAK-755 for the treatment of cTTP.

Koa Health appoints Dr. Anna Mandeville as UK Clinical Director and Leslie Norwalk to the Supervisory Board

Retrieved on: 
Wednesday, March 1, 2023
UCL, Biotechnology, Supervisory board, Centers for Medicare & Medicaid Services, Health, Quality management, Mental, Acacia koa, NHS, Neurocrine Biosciences, UK Clinical Pharmacy Association, International Advisory Council, American Mental Health Foundation, WHO, National Health Service, APCO Worldwide, Medicare, University College Hospital, Health Foundation, ModivCare, Hult International Business School, University College London Hospitals NHS Foundation Trust, Psychological Services, Quality, Mental health, Schonfeld Strategic Advisors, NuVasive, Nursing, Pharmaceutical industry

BOSTON, March 1, 2023 /PRNewswire-PRWeb/ -- Koa Health, a leading global provider of digital mental healthcare solutions, today announces that Dr. Anna Mandeville has joined the company's team as UK Clinical Director, and Leslie Norwalk has been appointed to the company's Supervisory Board. Anna will oversee the development of Koa Health's clinical services, and Leslie will serve as an advisor on the US healthcare system.

Key Points: 
  • Dr. Anna Mandeville joins as UK Clinical Director with over 25 years experience in the UK's National Health Service to oversee the development of the company's clinical services, and Leslie Norwalk will serve as a member of the Supervisory Board, advising on the US healthcare system.
  • BOSTON, March 1, 2023 /PRNewswire-PRWeb/ -- Koa Health , a leading global provider of digital mental healthcare solutions, today announces that Dr. Anna Mandeville has joined the company's team as UK Clinical Director, and Leslie Norwalk has been appointed to the company's Supervisory Board.
  • Anna will oversee the development of Koa Health's clinical services, and Leslie will serve as an advisor on the US healthcare system.
  • Consultant Clinical Psychologist Dr. Anna Mandeville joins Koa Health from the NHS, further strengthening the company's clinical expertise
    Dr. Oliver Harrison, CEO, Koa Health, said, "Around the world, people are grappling with the mental health impact of the cost-of-living crisis and political and economic instability (following three years of pandemic).

OstomyCure Announces Completion of Patient Recruitment Milestone in Pivotal TIES® Clinical Trial

Retrieved on: 
Wednesday, January 18, 2023
Hospital, Ileostomy, Quality of life, Safety, Patient, TIES, Clinical trial, University College Hospital, Pharmaceutical industry, Medical device, EU

STOCKHOLM and OSLO, Norway, Jan. 18, 2023 /PRNewswire/ -- OstomyCure, a clinical-stage medtech company developing revolutionary technologies to transform the lives of people with a stoma, today announced that it has successfully completed a crucial patient recruitment milestone in its pivotal clinical trial of the company's proprietary TIES implant technology.

Key Points: 
  • STOCKHOLM and OSLO, Norway, Jan. 18, 2023 /PRNewswire/ -- OstomyCure, a clinical-stage medtech company developing revolutionary technologies to transform the lives of people with a stoma, today announced that it has successfully completed a crucial patient recruitment milestone in its pivotal clinical trial of the company's proprietary TIES implant technology.
  • Patients will continue to be recruited during the regulatory process to further build clinical evidence for the device.
  • OstomyCure, CEO, Dr Johan Jarte, added, "Completing this milestone for our pivotal clinical trial is a crucial step in bringing this novel device closer to regulatory clearance and introducing it to a large patient population urgently in need of solutions to improve their quality of life.
  • We are incredibly grateful for the commitment and enthusiasm of patients and clinicians who have taken part in the trial."

OstomyCure Announces Completion of Patient Recruitment Milestone in Pivotal TIES® Clinical Trial

Retrieved on: 
Wednesday, January 18, 2023
Hospital, Ileostomy, Quality of life, Safety, Patient, TIES, Clinical trial, University College Hospital, Pharmaceutical industry, Medical device, EU

STOCKHOLM and OSLO, Norway, Jan. 18, 2023 /PRNewswire/ -- OstomyCure, a clinical-stage medtech company developing revolutionary technologies to transform the lives of people with a stoma, today announced that it has successfully completed a crucial patient recruitment milestone in its pivotal clinical trial of the company's proprietary TIES implant technology.

Key Points: 
  • STOCKHOLM and OSLO, Norway, Jan. 18, 2023 /PRNewswire/ -- OstomyCure, a clinical-stage medtech company developing revolutionary technologies to transform the lives of people with a stoma, today announced that it has successfully completed a crucial patient recruitment milestone in its pivotal clinical trial of the company's proprietary TIES implant technology.
  • Patients will continue to be recruited during the regulatory process to further build clinical evidence for the device.
  • OstomyCure, CEO, Dr Johan Jarte, added, "Completing this milestone for our pivotal clinical trial is a crucial step in bringing this novel device closer to regulatory clearance and introducing it to a large patient population urgently in need of solutions to improve their quality of life.
  • We are incredibly grateful for the commitment and enthusiasm of patients and clinicians who have taken part in the trial."

Noema Pharma Announces Completion of Enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) Validation Study

Retrieved on: 
Tuesday, September 6, 2022
Trigeminal nerve, UCL, University College Hospital, Pain, Trigeminal neuralgia, Noema, Sofinnova, Glutamate (neurotransmitter), Seizure, Brain, LIBRA, Sensation, Diagnosis, Self-assessment, Pain scale, Neuropathic pain, GLOBE, Â, Nerve injury, Company, Diary, Tourette syndrome, Data collection, Face, PDE10A, Polaris Partners, CNS, UCLH, Tuberous sclerosis complex tumor suppressors, Patient, Basimglurant, Medical device, Pharmaceutical industry, Research, Biotechnology

BASEL, Switzerland and BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces it has completed participant enrollment and data collection in the validation study of a novel Trigeminal Neuralgia Electronic Diary (TNED).

Key Points: 
  • BASEL, Switzerland and BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces it has completed participant enrollment and data collection in the validation study of a novel Trigeminal Neuralgia Electronic Diary (TNED).
  • Thirty participants with a confirmed diagnosis of trigeminal neuralgia (TN) volunteered to complete the electronic diary.
  • While the analysis of the validation data is ongoing, the electronic diary was generally found to be easy to use and enabled participants to accurately describe the burden of trigeminal neuralgia (TN).
  • In addition to being patient friendly and easy to use, TNED is the first electronic diary designed specifically for people who suffer from TN.

AUGS/IUGA Abstract: EnPlace® Minimally Invasive, Meshless, Ligament Fixation System Achieves 92.5% Patient Satisfaction

Retrieved on: 
Wednesday, July 13, 2022
Multimedia, University Health Network, Uterus, Patient satisfaction, CE marking, University College Hospital, Patient, MD, St Luke's, Dissection, University college, Woman, Uterine prolapse, FDA, Health, Birth control, Medicine, Medical device, EU

NEWARK, Del., July 13, 2022 /PRNewswire/ -- FEMSelect, the developer of EnPlace, a minimally invasive, meshless approach to pelvic floor ligament fixation, reported positive study results for the EnPlace system on women between the ages of 33-45.

Key Points: 
  • NEWARK, Del., July 13, 2022 /PRNewswire/ -- FEMSelect, the developer of EnPlace, a minimally invasive, meshless approach to pelvic floor ligament fixation, reported positive study results for the EnPlace system on women between the ages of 33-45.
  • The accepted abstract demonstrated overwhelmingly that the EnPlace approach to the management of symptomatic uterine prolapse in young women reached a very high level of patient satisfaction.
  • For the sacrospinous ligament fixation (SSLF) hysteropexy procedure, the overall patient satisfaction rate was 92.5 percent out of 100.
  • "This focused study on younger women confirms our overall experience with utilizing the EnPlace procedure over the past four years.